Risk Factors for Pancreatic Cancer and Cholangiocarcinoma

2021 ◽  
pp. 3-20
Author(s):  
Tsuyoshi Hamada ◽  
Yousuke Nakai
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer

Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age

2012 ◽  
Vol 48 (2) ◽  
pp. 238-246 ◽  
Author(s):  
Suguru Mizuno ◽  
Yousuke Nakai ◽  
Hiroyuki Isayama ◽  
Ayako Yanai ◽  
Naminatsu Takahara ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Screening Strategy ◽  
Onset Age ◽  
Diabetes Screening ◽  
Diabetes Onset ◽  
Early Signs

Fr336 RISK FACTORS FOR DEVELOPMENT OF PANCREATIC CANCER AMONG PATIENTS WITH CHRONIC PANCREATITIS: A CASE-CONTROL STUDY

2021 ◽  
Vol 160 (6) ◽  
pp. S-297-S-298
Author(s):  
Mark Kowalczyk ◽  
Sridevi K. Pokala ◽  
Joshua Demb ◽  
Fady Youssef ◽  
Lin Liu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds

2003 ◽  
Vol 124 (5) ◽  
pp. 1292-1299 ◽  
Author(s):  
Stephen J Rulyak ◽  
Albert B Lowenfels ◽  
Patrick Maisonneuve ◽  
Teresa A Brentnall
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Familial Pancreatic Cancer

scholarly journals Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer

2018 ◽  
Vol 118 (4) ◽  
pp. 555-567 ◽  
Author(s):  
Guido Eibl ◽  
Zobeida Cruz-Monserrate ◽  
Murray Korc ◽  
Maxim S. Petrov ◽  
Mark O. Goodarzi ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Pancreatic Cancer

scholarly journals Tobacco and alcohol as risk factors for pancreatic cancer

2017 ◽  
Vol 31 (5) ◽  
pp. 529-536 ◽  
Author(s):  
Murray Korc ◽  
Christie Y. Jeon ◽  
Mouad Edderkaoui ◽  
Stephen J. Pandol ◽  
Maxim S. Petrov
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer

scholarly journals Risk factors of clinically relevant pancreatic fistula after distal pancreatectomy for pancreatic cancer

Suizo ◽  
2017 ◽  
Vol 32 (2) ◽  
pp. 155-161
Author(s):  
Sokichi MATSUMOTO ◽  
Yusuke WATANABE ◽  
Kanako KURATA ◽  
Kazuyoshi NISHIHARA ◽  
Toru NAKANO
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Pancreatic Fistula ◽  
Distal Pancreatectomy

Risk Factors for Pancreatic Cancer

2021 ◽  
pp. 3-16
Author(s):  
Oskar Franklin ◽  
Malin Sund
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer

A Mendelian randomization analysis of known and putative risk factors for pancreatic cancer

Pancreatology ◽  
2019 ◽  
Vol 19 ◽  
pp. S97-S98
Author(s):  
Ye Lu ◽  
Manuel Gentiluomo ◽  
Luca Morelli ◽  
Ofure Obazee ◽  
Federico Canzian ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Mendelian Randomization ◽  
Mendelian Randomization Analysis ◽  
Randomization Analysis

Risk Factors for Gemcitabine-Induced Vascular Pain in Patients With Pancreatic Cancer

2020 ◽  
pp. 106002802096935
Author(s):  
Shigeru Ishida ◽  
Yoko Makihara ◽  
Hiroyuki Watanabe ◽  
Takafumi Nakashima ◽  
Kenichiro Nagata ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Cancer ◽  
Predictive Factors ◽  
Preventive Measures ◽  
Regression Analyses ◽  
Multivariable Analyses ◽  
Vascular Pain ◽  
Pain Symptoms ◽  
Gemcitabine Treatment ◽  
Hot Pack

Background: Peripheral intravenous injection of gemcitabine often causes vascular pain; however, preventive measures have not yet been established. Objectives: This study focused on identifying predictive factors for gemcitabine-induced vascular pain. Methods: We retrospectively analyzed risk factors for developing vascular pain in patients with pancreatic cancer receiving gemcitabine infusions at our institution. Infusions were divided into groups according to presence or absence of vascular pain symptoms, and variables were compared. Odds ratios for risk factors were calculated using logistic regression analyses. Results: Overall, 272 patients with pancreatic cancer were subjected to 725 gemcitabine infusions, and of these, 18.4% (n = 50) experienced vascular pain. There were significant differences in the gemcitabine dose ( P = 0.025), dose of gemcitabine/body surface area (BSA; P = 0.004), concentration of gemcitabine ( P = 0.025), and hot pack use ( P = 0.011) between the vascular pain and no vascular pain groups. Multivariable analyses indicated that gemcitabine dose/BSA and lack of hot pack use were risk factors for developing vascular pain. Moreover, on administration of a higher dosage (>930 mg/m2), the incidence of vascular pain in patients using a hot pack (6.7%) was significantly lower than that in patients not provided a hot pack (16.2%). Conclusions and Relevance: High gemcitabine dosages and lack of hot pack use were predictive factors for gemcitabine-induced vascular pain in patients with pancreatic cancer. Patients receiving gemcitabine treatment should apply a hot pack to the injection site. Scrupulous clinical attention is required for patients presenting with these risk factors to improve pain management.

Sign in / Sign up

Export Citation Format

Share Document